Circulating biomarkers of bronchoalveolar epithelial and endothelial injury in healthy controls and patients with moderate to severe COVID-19 pneumonia

These files include the raw data of five circulating biomarkers of bronchoalveolar epithelial and endothelial injury collected in the serum of 20 healthy controls and 54 COVID-19 patients with moderate to severe pneumonia within 48 h of hospital admission: Krebs von den Lungen-6 (KL-6), soluble receptor for advanced glycation end-products (sRAGE), club cell protein 16 (CC16), angiopoietin-2 (Ang-2), and soluble CD146 (sCD146). Additionally, the raw data of six laboratory indices (creatinine, C-reactive protein (CRP), lactate dehydrogenase (LDH), ferritin, D-dimer, and neutrophil/lymphocyte ratio (NLR)), two computed tomography-related parameters (percentage of opacity, and percentage of high opacity), a respiratory severity index (ratio of peripheral oxygen saturation to inspired oxygen fraction (SpO2/FIO2)), and a severity score (Sequential Organ Failure Assessment (SOFA)) were recorded.

COVID-19 subgroups were defined according to the maximal level of respiratory support received during hospitalization on the World Health Organization clinical progression scale (WHO-CPS): oxygen by mask or nasal prong (O2), high flow oxygen therapy (HFOT), and mechanical ventilation (MV). COVID-19 patients were next stratified by the need for mechanical ventilation (MV) during hospitalization. Complete biomarker kinetics (D0, 7, and 14) were available for 44 COVID-19.